GlassScriptPhysician profile
Constance Daphne Wash
NPI 1932148384
$9,188.07
in general payments reported to CMS, 2019-2025
37 companies · $411 in 2025
The $411 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $846 · 2020: $3,188 · 2021: $1,377 · 2022: $1,738 · 2023: $1,060 · 2024: $569 · 2025: $411.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,679 · Education: $194 · Long Term Medical Supply Or Device Loan: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,678.99 |
| Education | $193.93 |
| Long Term Medical Supply Or Device Loan | $166.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $3,117.43 | 2019-2025 | |
| Allergan, INC. | $1,227.35 | 2020 | |
| Amgen INC. | $603.48 | 2019-2025 | Kyprolis, Imdelltra (Amg757), Lumakras |
| Bayer Healthcare Pharmaceuticals INC. | $575.69 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $487.56 | 2019-2023 | Opdivo |
| Merck Sharp & Dohme LLC | $449.43 | 2019-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Daiichi Sankyo INC. | $400.69 | 2021-2025 | Enhertu |
| Janssen Biotech, INC. | $355.97 | 2019-2025 | Darzalex, Tecvayli, Rybrevant |
| Rigel Pharmaceuticals, INC. | $318.37 | 2021-2025 | Rezlidhia, Tavalisse, Gavreto |
| Seagen INC. | $209.25 | 2020-2022 | |
| Puma Biotechnology, INC. | $147.59 | 2019-2022 | |
| Adaptive Biotechnologies Corporation | $141.64 | 2022-2024 | Clonoseq |
| Astrazeneca Pharmaceuticals LP | $131.99 | 2019-2024 | Enhertu, Tagrisso |
| Gilead Sciences, INC. | $131.21 | 2022-2025 | Trodelvy |
| Lilly USA, LLC | $130.13 | 2021-2023 | Retevmo, Jaypirca, Verzenio |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $79.60 | 2021-2023 | Ninlaro |
| Celgene Corporation | $58.25 | 2019-2024 | Reblozyl |
| Array Biopharma INC | $53.53 | 2022-2024 | Braftovi, Mektovi, Lorbrena |
| Pfizer INC. | $48.16 | 2023-2025 | |
| Incyte Corporation | $46.76 | 2019-2025 | Jakafi |
| Glaxosmithkline, LLC. | $46.14 | 2020-2021 | |
| Astellas Pharma US INC | $42.10 | 2023-2025 | Vyloy, Xospata |
| Dova Pharmaceuticals | $34.53 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.19 | 2021-2022 | |
| Blueprint Medicines Corporation | $34.07 | 2024 | Ayvakit |
| Beigene USA, INC. | $33.41 | 2021-2023 | Brukinsa |
| Genzyme Corporation | $31.57 | 2019-2022 | |
| Pharmaessentia USA Corporation | $29.87 | 2023 | Besremi |
| Kite Pharma, INC. | $29.82 | 2020-2021 | |
| Mirati Therapeutics, INC. | $27.14 | 2023 | Krazati |
| Exelixis INC. | $26.75 | 2019-2022 | |
| Genentech USA, INC. | $22.59 | 2023 | |
| Aveo Pharmaceuticals, INC. | $21.32 | 2024 | |
| Foundation Medicine, INC. | $16.01 | 2023 | Foundationone Liquid Cdx |
| Pharmacosmos Therapeutics INC. | $15.51 | 2025 | Monoferric |
| Emd Serono, INC. | $15.26 | 2025 | |
| Karyopharm Therapeutics INC. | $13.71 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Constance Wash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.